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1. Introduction 
There had been a tremendous advancement in the quality and quantity of worldwide research 
production in the field of microbiology. Among various biomedical fields, microbiology has 
been the subject of extensive study due to the problems imposed on human health by 
countless infectious diseases known so far. Identification of infectious agents and to adapt 
measures for its eradication is considered a major tool for alleviating human from the burden 
of infections. Progressively it is important to modulate the structure of earlier marketed 
antibacterial agents to produce newer agents with superior antimicrobial profile.  
Fluoroquinolones, useful in the treatment of many bacterial infections, attacks DNA gyrase 
and topoisomerase IV on bacterial chromosomal DNA (Ball et al., 1998, Blandeau, 1999). 
However, widespread use of fluoroquinolones has caused the resistant rates of various 
Gram-negative bacilli (e.g., Pseudomonas aeruginosa, Escherichia coli, and Salmonella), to 
approach the critical points. 
To solve the problem of increasing antimicrobial resistance, it is crucial to design and 
produce new quinolones that could provide effective therapy for infections caused by 
organisms resistant to older agents. Most of the quinolones currently on the market or those 
which are under development, displays only moderate activity against many Gram-positive 
cocci, including Staphylococci and Streptococci. This insufficient activity has not only 
limited their use in infections caused by these organisms, such as respiratory tract infections, 
but has also been believed to be one of the reasons for the rapidly developing quinolone 
resistance. Therefore, recent efforts have been directed toward the synthesis of new 
quinolone antibacterials that can provide improved Gram-positive antibacterial activity, 
while retaining good Gram-negative activity 
The extensive research efforts have enabled a better definition of the structural moieties  
or elements around the basic pharmacophore of quinolones that offer the best combination  
of clinical efficacy and reduced resistance selection in Gram-positive and Gram negative 
bacteria.  
The general structure of quinolone antibacterial agents consist of a 1-substituteted-1,4 dihydro-
4-oxopyridine-3-carboxylic moiety A combined with an aromatic or hetero-aromatic ring B.  
 









Most of the current agents have a carboxyl group at position 3, a keto group at position 4, a 
fluorine atom at position 6, and a nitrogen heterocycle moiety at the C-7 position (Sarro & 
Sarro, 2001). In addition at the C-7 position, substitution of bulky functional groups is 
permitted (Emami et al., 2006). The substituent at N-1 and C-8 positions of the quinolones 
should be relatively small and lipophilic to enhance self-association and also control potency 
and pharmacokinetics. Groups at C-5 and C-6 position controls potency for Gram-positive 
activity. SAR studies on quinolones explain that C-3 and C-7 positions are vital for 
antibacterial activities.   
Most of the quinolone antibacterial research has been focused on the functionality at C-7 
position as it is the most adaptable site for chemical change (Anderson & Osheroff, 2001, 
Foroumadi et al., 2005) 416. The 3-carboxylic group is considered important for DNA gyrase 
binding (Chu et al., 1985, Domagala et al., 1988, Sarro & Sarro, 2001). Modifications on this 
position of quinolone are normally not accepted (Mitscher, 2005). However, there are some 
exceptions to this rule; of which, one was ester pro-drug analogues that were converted in-
vivo back to the acid (Kondo et al., 1988). In one case, replacement of 3-carboxylic acid group 
of ciprofloxacin with bioisostere- fused isothiazolo ring was found more potent (4 to 10 
times) than ciprofloxacin and possessed enhanced activity against DNA gyrase (Chu & 
Fernandes, 1989). A series of the C3/C3 bis-fluoroquinolones tethered with an 1, 3, 4-
oxadiazole ring were reported showing antitumor activity (Hu et al., 2012) while 1,8 
Imidazo fused quinolones exhibited moderate antibacterial activity (Venkat Reddy et al., 
2009). Recently two naphthyl ester quinolone derivatives have been reported to demonstrate 
photo-oxidant properties (Vargas et al., 2008).   
Advances in quinolone field are likely to provide better compounds capable of dealing with 
the resistant strains. These research efforts have been rewarded by very significant 
improvements in antibacterial potency as well as in vivo efficacy. It is evident from literature 
that most of the research on quinolone is directed towards group modification of the C-7 
basic group of the quinolone and the effect of substitution at C-3 position of quinolones has 
not been studied to a large extent to produce new agents with better antimicrobial profile. 
Accordingly to explore the potential of 3-carboxylic quinolone derivatives as anti Gram 
positive and Gram negative agents, we have recently reported some novel enoxacin (Saeed 
Arayne et al., 2009) , levofloxacin (Sultana et al., 2011) and ofloxacin (Arayne et al., 2012) 
carboxamide analogues by introducing new functionality at C-3 position. In continuation of 
our research program to establish the structure-activity relationships of 3-carboxylic 
quinolone derivatives, we here in report some novel enoxacin analogues which have been 
prepared by introducing new functionality at C-3. These compounds were prepared by two 
series of reactions. In reaction 1, the carboxylic group at C-3 position of enoxacin was 
esterified in methanol followed by reaction 2, whereby the ester group was subjected to 
nucleophilic attack at the carbonyl carbon by various aliphatic (urea, thiourea, acetamide, 
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thioacetamide) and aromatic amines (phthalimide, benzamide) yielding amides and 
regenerating alcohols. 
2. Experimantal 
2.1 Physical measurements 
Melting points were obtained manually by capillary method. Infrared spectra were recorded 
on FT-IR spectrophotometer (shimadzu prestige-21 200 VCE coupled to a P IV- PC and 
loaded with IR solution version 1.2 software). The potassium bromide disks were placed in 
the holder directly in the IR laser beam. Spectra were recorded at a resolution of 2 cm-1 and 
50 scans were accumulated. NMR spectra were recorded on Bruker FT - NMR 500 MHz with 
the compounds dissolved in DMSO. Chemical shifts are reported in parts per million (δ) 
relative to tetra methyl silane as an internal standard. Significant 1H NMR data are tabulated 
in the following order: number of proton(s) and multiplicity (s, singlet; d, doublet; t, triplet; 
q, quartet; and m, multiplet). The mass spectra were recorded on Finnign-MAT212 under 
electron impact (EI) ionization condition. Thin layer chromatography (TLC) was performed 
on HSF-254 TLC plate and compounds visualized under UV lamp. 
2.2 Antibacterial studies 
Disk Diffusion technique developed by Bauer et al (Baur et al., 1966) was adopted to 
determine the antibacterial activity of enoxacin and its derivatives against 10 different 
clinical isolates of Gram positive (Staphylococcus aureus, Bacillus subtilis, Streptococcus 
pneumoniae) and Gram negative organisms (Klebsiella Pneumoniae, Proteus mirabilis, Shigella 
flexneri, Escherichia coli, Pseudomonas areuginosa, Citrobacter species, and Salmonella typhi). 
50 µg mL-1 stock solutions of the drug and their derivatives were prepared in hot methanol. 
The stock solution was diluted to 3 different concentrations i.e. 5, 10 and 20 µg mL-1. 
Commercially available filter paper discs were impregnated with the prepared solutions of 
the drug and the derivatives, dried and applied on the surface of the agar plate over which a 
culture of micro organism was already streaked. After 24 hours of incubation the clear zone 
of inhibition around the disc was determined, this is proportional to the bacterial 
susceptibility for the antimicrobial agent present in the disk. Three replicas were made for 
each treatment to minimize error. 
2.3 Antifungal studies 
Enoxacin and its derivatives were tested for antifungal activity against the fungi; Aspergillus 
purasiticus, Saccharomyces cervics, Candida albicans and Fusraium solani. 
100 µg mL-1 stock solutions of the compounds were prepared in hot methanol. The stock 
solutions were diluted to 3 different concentrations i.e. 30, 40 and 50 µg mL-1. Commercially 
available filter paper discs were impregnated with the prepared solutions of the drugs and 
the compounds under study, dried and applied on the surface of the agar plate over which a 
culture of micro organism was already streaked. After 24 hours of incubation the clear zone 
of inhibition around the disc was determined, this is proportional to the fungal 
susceptibility for the antimicrobial agent present in the disk. Three replicas were made for 
each treatment to minimize error. 
 
A Search for Antibacterial Agents 
 
238 
2.4 Phagocyte chemiluminescence assay 
The assay was performed as described by Helfand et al. protocol (Helfand et al., 1982). 
Briefly enoxacin and its derivatives were diluted in three concentrations, (0.5, 5 and 25 µg 
mL-1) in Hanks Balanced Salt Solution containing calcium and magnesium (HBSS++). 25 µL 
diluted blood (1:50 dilution in sterile PBS, pH 7.4) or polymorphoneutrophils or mouse 
peritoneal macrophages (1x 106 mL-1) were added to the culture reaction. After 15 minutes of 
incubation for whole blood and 30 minutes for isolated cells, 25 µL (7 x 105 M)  luminol (G-
9382 Sigma Chemical Co. USA) or 25 µL (0.5 mM) lucigenin were added, followed by 25 µL 
(20 mg mL-1) SOZ (Sigma Chemical Co. USA) or 25 µL (40 nM) PMA. 
HBSS++ alone was run as a control. The level of ROS for the compounds was monitored for 
50 minutes by the Luminometer (Luminoskan RS, Labsystems, Finland).  The total ROS level 
was recorded as total light produced and recorded during 50 minutes scan. 
2.5 T-Cell proliferation assay 
Cell proliferation was evaluated by standard thymidine incorporation assay following a 
method reported by Nielsen et al. (Nielsen et al., 2000). 10 mL blood was collected by vein 
puncture in heparin containing tube from a healthy volunteer. 50 mL sterile falcon tube was 
placed in safety cabinet (at sterile conditions) to this was added blood, ficoll paque and 
RPMI incomplete media (without fetal bovine serum) in equal volume. 5 mL ficoll paque 
was added in three 15 mL sterile empty centrifuge tubes and centrifuged at 400xg for 20 
minutes at room temperature with no break. Peripheral blood mononuclear cells (PBMCs) 
appeared at the junction of two layers, the upper layer was discarded and the lower 
containing the PBMCs was transferred in another sterile tube, washed with RPMI 
incomplete media and centrifuged again at 300xg for 10 minutes at 4ºC. The supernatant 
was discarded and re-suspended pellet in 1mL RPMI incomplete media and stored on ice. 
The viability of the cells was checked by trypan blue and cells were counted by 
hemocytometer. 50 µL of 5% complete RPMI was added into each well of a sterile 96 well  
plate in sterile environment using safety cabinet followed by samples (drug and its 
derivatives) having the concentration  between 6.25 and 100 µg mL-1 and adjusting the final 
volume to 0.3 mL. While well ‘A’ contained only 5% complete RPMI to be used as control. 
50 µL PBMC cells (1x106/mL) were added in suspension of 5% complete RPMI to each well 
except blank followed by the addition of 50 µL PHA except negative control and blank and 
volume of well was made up to 0.2 mL by 5% complete RPMI .The mixture was incubated 
for 72 hours in CO2 incubator at 37ºC. After incubation 25 µL of thymidine was added in 
each well except blank and the plate again incubated in CO2 incubator at 37ºC for 18 hours. 
After incubation cells were harvested using glass fiber filter and the cell harvester. In cell 
harvesting the plates were washed with 70% ethanol 5 times, filtered and left until they 
were completely dry, then dissolved in separate vials using the scintillation solution and 
scanned by scintillation counter. 
2.6 Cytokinne production from mononuclear cells 
The monocytes were grown in 75 mm2 flask in RPMI–1640 supplemented with 10% FBS 
until they attained 70% confluency and passaged twice a week. On reaching confluency 
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the cells were plated in 24-well tissue culture plates at a concentration of 2.5×10-5 
cells/mL. The cells were differentiated into macrophage like cells by using phorbol 
myristate acetate (PMA) at a final concentration of 20 ng mL-1 and incubated at 37ºC in 5% 
CO2 for 24 hours. 
After 24 hr incubation with PMA, cells were stimulated with bacterial lipopolysaccharide 
(LPS) 50 ng mL-1 and treated with compounds (drug and its derivatives) at a 
concentration of 25 µg mL-1 and incubated for 4 hours at 37ºC in 5% CO2. The 
supernatants were collected after 4 hrs which was then analyzed for the level of TNF-α. 
The plate was incubated for further 18 hrs and then supernatants were collected for the 
analysis of IL-1β level. Human TNF-α and IL-1β Duo set Kits (R&D systems, Minneapolis, 
USA) were used for cytokine quantification according to manufacturer’s instructions 
(Singh et al., 2005). 
2.7 General procedure for preparation of derivatives (A6-A12) 
Enoxacin and all the chemicals used were of analytical grade. Amines used for the synthesis 
were urea, thiourea, acetamide, thioacetamide, hydroxylamine, benzamide and 





















Enoxacin Ester intermediate  
 
Fig. 2. Synthesis of ester intermediate 
0.01 mole of enoxacin (3.21 g) was dissolved in hot methanol (80 mL) to which 1.2 mL 
sulphuric acid was added and the solution was refluxed for about 7-8 hours till the 
consumption of drug in ester formation (monitered by TLC). The solution was cooled 
down to room temperature and the precipitate obtained was washed with chloroform and 
dried for 1 hour at 80°C to give methyl ester of the drugs. The corresponding esters were 
subjected to nucleophilic attack by adding 0.01 molar methanol solutions of amines 
respectively with continuous stirring to generate carboxamides. While for compound A11 
and A12, NaOH was added in the methanolic mixture of benzamide and phthalimide and 
warmed for 30 mins prior to their addition in the reaction flask containing enoxacin ester 
intermediate. The reaction was refluxed for about 2-3 hours till completion, indicated by 
TLC. The volume of the reaction mixture was then reduced by rotary-evaporation. The 
precipitates were filtrated off, washed with chloroform and re-crystallized from 
methanol-chloroform (2:8) mixture till pure compounds were achieved (checked on TLC 
and constant melting point). 
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Fig. 3. Synthesis of compound A6-A12 
3. Result and disscussion 
3.1 Spectral analysis 
3.1.1 IR studies 
In the IR spectrum of enoxacin, the OH stretching vibration of carboxylic acid appeared as a 
broad band in the range 3500–3100 cm–1 and interfered with the NH stretching vibration of 
the secondary amino group of the piperyzinyl ring which absorbed in the same region at 
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3100 cm–1. Two strong carbonyl absorptions at 1690 and 1640 cm–1 were observed due to the 
presence of keto carboxylic acid. 
The spectra of all the compounds showed absence of acidic OH peak of enoxacin and a 
distinct, strong and un-obscured NH stretch was observed near 3200-3100 cm–1 indicating that 
carboxylic site reacted with the selected amines forming amides. However compound A10 
showed a sharp band at 3300 cm–1 due to the presence of hydroxyl group in their structure. 
While compounds A7 and A9 showed a medium intensity band near 2100 cm–1 due to the 
presence of C=S group, additionally, IR spectra of the compounds revealed that carbonyl 
absorption of carboxylic group shifted towards right near 1665-1640 cm–1 in the spectra of all 




Important 1H NMR signals of enoxacin were observed at chemical shifts of  1.40 (t, 3H, J = 
7.0 Hz, -CH3 methyl), 2.0 (s, 1H, amine), 2.62 (s, 4H, piperazine), 3.85 (s, 4H, piperazine), 4.48 
(q, 2H, J = 7.0 Hz, -CH2- ethyl), 8.10, 8.95 (s, 2H, naphthyridine) and 11.0 (s, 1H, COOH). On 
comparing main peaks of enoxacin with its derivatives, all the signals of enoxacin were 
present in the 1HNMR spectra of the compounds except the acidic proton resonance at 9.8 
ppm. Moreover, all these derivatives displayed resonance of naphthyridine protons down-
field by (0.4-0.7ppm). Unlike enoxacin all the derivatives showed a singlet in the region 7.9-
8.0 ppm which corresponds to the absorption of sec-amide. Further, the spectra of the 
compounds also exhibited other signals corresponding to their respective chemical structure 
(mentioned in the spectral data). The signals for the aliphatic and piperazine protons were 
practically unchanged since they lie far from the reaction site of the drug.  
3.1.3 Mass spectrometric studies 
1. The electron impact mass spectrum (EIMS) of enoxacin showed molecular ion (M+) 
peak at (m/z, %): (320, 35). However compounds (A6-A12) showed a very low 
percentage of M+ peaks with respect to their proposed structures. 
3.1.4 Spectral data of compounds A6-A12 
A6 1-(1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-
carbonyl)urea 
M.p. 257°C IR (KBr) νmax: 1655, 1625 (C=O) and 3150 (N-H) cm-1, 1H NMR (DMSO, 500 
MHz) 1.41 (t, 3H, J = 7.2 Hz, -CH3 ethyl), 2.59 (s, 4H, piperazine), 3.84 (s, 4H, 
piperazine), 5.6 (s, 4H, amine), 4.45 (q, 2H, J = 7.0 Hz, -CH2- ethyl), 7.98 (s, 1H, sec. 
amide), 8.20 (d, 1H, H5-naphthyridine, JH,F = 12.49 Hz), 9.18 (s, 1H, H2-naphthyridine), 
MS (m/z, %): (362, 10.5) M+. 
A7 1-(1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-
carbonyl)thiourea 
M.p. 287°C IR (KBr) νmax: 1655, 1630 (C=O), 2100 (C=S), 3300 (OH), 3200 (N-H) and 2100 
(C=S) cm-1, 1H NMR (DMSO, 500 MHz) 1.43 (t, 3H, J = 7.1 Hz, -CH3 ethyl), 2.62 (s, 4H, 
piperazine), 3.83 (s, 4H, piperazine), 4.2 (s, 4H, amine), 4.45 (q, 2H, J = 7.2 Hz, -CH2- 
ethyl), 7.95 (s, 1H, sec. amide), 8.21 (d, 1H, H5-naphthyridine, JH,F = 12.51 Hz), 9.19 (s, 
1H, H2-naphthyridine), MS (m/z, %): (378, 9.5) M+. 
 





M.p. 295°C IR (KBr) νmax: 1655, 1630 (C=O) and 3140 (N-H) cm-1, 1H NMR (DMSO, 500 
MHz) 1.42 (t, 3H, J = 7.0 Hz, -CH3 ethyl), 2.02 (s, 3H, methyl), 2.61 (s, 4H, piperazine), 
3.84 (s, 4H, piperazine), 4.46 (q, 2H, J = 7.1 Hz, -CH2- ethyl), 7.85 (s, 1H, sec. amide), 8.21 
(d, 1H, H5-naphthyridine, JH,F = 12.56 Hz), 9.19 (s, 1H, H2-naphthyridine), MS (m/z, %): 
(361, 89.5) M+. 
A9 N-ethanethioyl-1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-
naphthyridine-3-carboxamide 
M.p. 237°C IR (KBr) νmax: 1645, 1628 (C=O), 2100 (C=S), 3300 (OH), 3150 (N-H) and 2120 
(C=S) cm-1, 1H NMR (DMSO, 500 MHz) 1.41 (t, 3H, J = 7.1 Hz, -CH3 ethyl), 2.529 (s, 3H, 
methyl), 2.62 (s, 4H, piperazine), 3.81 (s, 4H, piperazine), 4.44 (q, 2H, J = 6.9 Hz, -CH2- 
ethyl), 7.98 (s, 1H, sec. amide), 8.21 (d, 1H, H5-naphthyridine, JH,F = 12.54 Hz), 9.19 (s, 
1H, H2-naphthyridine), MS (m/z, %): (377, 5.5) M+. 
A10 1-ethyl-6-fluoro-N-hydroxy-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-
carboxamide 
M.p. 267°C IR (KBr) νmax: 1655, 1634 (C=O), 3300 (OH) and 3180 (N-H) cm-1, 1H NMR 
(DMSO, 500 MHz) 1.43 (t, 3H, J = 7.0 Hz, -CH3 ethyl), 2.62 (s, 4H, piperazine), 3.84 (s, 
4H, piperazine), 4.45 (q, 2H, J = 7.0 Hz, -CH2- ethyl), 6.58 (s, 1H, OH), 7.97 (s, 1H, sec. 
amide), 8.18 (d, 1H, H5-naphthyridine, JH,F = 12.56 Hz), 9.09 (s, 1H, H2-naphthyridine), 
MS (m/z, %): (335, 11) M+. 
A11 N-benzoyl-1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-
carboxamide 
M.p. 255°C IR (KBr) νmax: 1645, 1635 (C=O) and 3155 (N-H) cm-1, 1H NMR (DMSO, 500 
MHz) 1.42 (t, 3H, J = 7.0 Hz, -CH3 ethyl), 2.62 (s, 4H, piperazine), 3.86 (s, 4H, 
piperazine), 4.43 (q, 2H, J = 7.0 Hz, -CH2- ethyl), 7.21 (m, 5H, phenylic H),  7.99 (s, 1H, 
sec. amide), 8.18 (d, 1H, H5-naphthyridine, JH,F = 12.56 Hz), 9.1 (s, 1H, H2-
naphthyridine), MS (m/z, %): (423, 7) M+. 
A12 2-(1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-
carbonyl)isoindoline-1,3-dione 
M.p. 278°C IR (KBr) νmax: 1655, 1630 (C=O) and 3150 (N-H) cm-1, 1H NMR (DMSO, 500 
MHz) 1.43 (t, 3H, J = 7.0 Hz, -CH3 ethyl), 2.60 (s, 4H, piperazine), 3.85 (s, 4H, 
piperazine), 4.45 (q, 2H, J = 7.0 Hz, -CH2- ethyl), 7.69 (s, 2H, phenylic H), 8.3 (s, 2H, 
phenylic H), 7.94 (s, 1H, sec. amide), 8.15 (d, 1H, H5-naphthyridine, JH,F = 12.56 Hz), 9.09 
(s, 1H, H2-naphthyridine), MS (m/z, %): (449, 10) M+. 
3.2 Antimicrobial studies 
3.2.1 Antibacterial activity 
All compounds showed activities nearly similar to enoxacin against all the Gram-positive test 
strains. Generally, the 7-piperazinyl enoxacin have better Gram-negative than Gram-positive 
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antimicrobial potency (Chin & Neu, 1983, Paton & Reeves, 1988, Wood, 1989). Studies 
revealed that the mode of action of quinolones involves inhibition of essential type II 
bacterial topoisomerases such as DNA gyrase and topoisomerase IV (Sissi & Palumbo, 
2003). Commonly DNA gyrase is more sensitive to Gram-negative bacteria and 
topoisomerase IV more sensitive to Gram-positive bacteria. As topoisomerase IV is the 
primary target of the quinolones with bulky functional group at N-4 position of piperazine 
ring, therefore the activities of all the compounds were found to be similar to enoxacin. 
However, against all the Gram-negative organisms, strong improvement in the 
antibacterial activity of the derivatives A11, A12 and A6 was observed in comparision to 
enoxacin (Tables 1 and 2). The increase in activity was greatest against Salmonella typhi, 
Pseudomonas aeruginosa and Escherichia coli. The enhancement in the antibacterial activity 
of these compounds might be a result of better interaction with DNA gyrase. It was 
observed that the activity of compounds A7-A10 decreased against all the Gram-negative 
strains.  It is proposed that in terms of structure–activity relationship, the antibacterial 
activity profile of enoxacin derivatives against Gram-negative bacteria was enhanced by 
the phenyl attachment via amide linkage at the 3-position of the enoxacin molecule. While 
reaction with aliphatic amines caused a diminution in antibacterial activity of enoxacin, 





Fig. 4. Base pairing between adenine/thymine & cytosine/guanine 
Previous studies showed that carboxylic group of quinolones was necessary to bind to 
bacterial DNA gyrase through hydrogen bonding. Looking at the structure of DNA, it is 
apparent that the hydrogen bonding between the two DNA strands is also through the 
amide group of heterocyclic bases. 
Since the inhibitory action of quinolones is not simply accomplished by inhibiting the 
bacterial enzyme function but they also actively poison cells by trapping the two 
topoisomerases on DNA as drug/enzyme/DNA complexes in which double-strand DNA 
breaks are held together by protein. It is proposed that converting carboxylic group into 
amide group would help quinolone to better undergo binding with bacterial DNA due to 
structural complementarities.  
 







3.2.1 Antifungal activity 
Quinolone antibiotics have been shown to be potent inhibitors of DNA gyrase and have 
been useful antibacterial drugs in clinical practice (Marklein, 1996). Laboratory work has 
indicated that inhibition of DNA gyrase is not specific and activity against nonbacterial 
targets has been shown (Dykstra et al., 1994, Fostel et al., 1996). Nakajima et al., (Nakajima et 
al., 1995) have reported that quinolone augmented the activity of amphotericin B and 
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fluconazole against a variety of fungi in both in vitro and in vivo assays of combined 
antifungal activity. Based on theses studies, we aimed to evaluate the antifungal activities of 
enoxacin and its derivatives against common fungal pathogens; Aspergillus purasiticus, 
Saccharomyces cervics, Candida albicans and Fusraium solani. Results show that except 
compound A6, none of the tested compounds possessed clinically useful antifungal activity. 
Compound A6 showed moderate inhibitory activity against Candida albicans (zone of 
inhibition = 17mm). The increased activity is probably due to some intracellular interaction 
of the derivative within the fungal cell; however the mechanism of the observed antifungal 
effect is still warranted (Sugar et al., 1997). 
3.3 Immunomodulatory activities 
Fluoroquinolones have been studied for their modulatory activity on the immune response. 
The best investigated agent seems to be moxifloxacin which showed immunomodulatory 
actions both in vitro and in vivo. However, the molecular mechanism causing the 
immunomodulatory effects of fluoroquinolones are still under investigation (Tauber & Nau, 
2008). Recently we have reported few carboxamide analogues of enoxacin showing 
potentials to mediate immune response. 
In order to test the immunomodulatory effect of enoxacin and its derivatives, we 
investigated their effect on phagocytosis, T-cell proliferation and cytokine release 
(particularly IL-1β and TNF-α) by macrophages. 
3.3.1 Effect on phagocytes oxidative burst 
Phagocytic cells on activation induce release of reactive oxygen species (oxidative burst) 
which is then quantified by a luminol- lucigenin enhanced chemiluminescence assay. With 
the luminol probe which detects the intracellular ROS using serum opsonize zymosan as 
activator, compounds A11 and A12 showed moderate inhibition on whole blood (IC50 10.5 
and 14.4µgmL-1 respectively). Similar inhibitory effects were observed on the isolated 
neutrophils (IC50 = 11.2 and 13.6µgmL-1 respectively) and on macrophages (IC50, 13.2 and 
11.4µgmL-1). In another set of experiment lucigenin probe and PMA as activator were used 
as a replacement for luminol and SOZ, only compounds A12 again demonstrated a 
moderate inhibition on the isolated neutrophils (12.6 µgmL-1 ) respectively). Enoxacin and 
other compounds did not exert any significant inhibition up to the highest concentration 
(25µgmL-1) in the system tested. 
3.3.2 Effect on T-cell proliferation 
The anti-proliferation of the test compounds was determined by measuring the inhibition of 
(PHA)-induced T-cell proliferation by determining radioactive thymidine incorporation. 
Results show (Figure 7) that compound A11 significantly suppressed T-cell proliferation in 
dose dependent manner. A dose as low as 3.15µgmL-1 of compound A11 caused 
approximately 50% reduction in T cell proliferation compared to control. While enoxacin 
and other compounds did not have any effect on T-cell proliferation up to the highest 
concentration (50µgmL-1) in the system tested.  
Figure 5 shows the immunomodulatory effects of compound A11 exhibiting prominent 
effect on PHA-induced T-cell proliferation. Cells were incubated with different 
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concentrations of the test compound in RMPI along with PHA for 72 hrs at 37ºC in CO2 
environment. Cells were further incubated for 18 hrs after the addition of thymidine [H]3 
and the radioactivity count as CPM reading was recorded using scintillation counter. The 
effect of compound on the T-cell proliferation is compared with the control. Each plot and 
error bar represents readings ± SD of three repeats. 
 
Fig. 5. Immunomodulatory effects of compound A-11 
3.3.3 Effect on cytokine release by macrophages 
The immuno-suppressive effect of enoxacin and its derivatives were tested on the release of 
selected cytokines including IL-1β and TNF-α by PHA-induced macrophages. Only 
compound A11 at concentration of 25µgmL-1 fairly suppressed the production of TNF-α 
showing 70% inhibition. Enoxacin and other compounds demonstrated no effect on any of 
the tested cytokines released form activated macrophages. 
4. Conclusion 
In conclusion we have synthesized some novel enoxacin derivatives bearing various 
aliphatic and aromatic substituents at C3 position via amide linkage. It was found that 
introduction of amide linkge with phenyl substituent at C3 position, produced noticeable 
enhancement in the in vitro activity of enoxacin particularly against Gram negative 
organism. In addition, unlike enoxacin, Compound A6 also exhibited effective anti-fungal 
activity against Candida albicans. Moreover, the phagocytic function, T-cell proliferation and 
cytokine release was moderately affected in presence of compounds A11 and A12, thus 
showing potentials to be anti-inflammatory. Conclusively, the test compounds showing 
diverse beneficial biological activities could serve as new lead molecular entities for treating 
various conditions such as infections, organ transplantation, cancer and for the treatment of 
rheumatoid arthritis and related autoimmune disorders. However, appropriate clinical trials 
are necessary before using the antimicrobial and immunomodulatory property of the test 
compounds in clinical practice. 
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